Breast cancer drug ribociclib made available Long-Term in new study
NCT ID NCT05161195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while researchers monitor long-term safety and how well the cancer is controlled. The goal is to ensure patients can stay on a treatment that is working for them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib (a targeted cancer drug) taken alone or with other drugs like letrozole, anastrozole, goserelin, or tamoxifen
What this could lead to
If successful, this study could confirm that ribociclib is safe and effective for long-term use in metastatic breast cancer, supporting its continued availability.
What could go wrong
This is a roll-over study, not a new treatment test, so it won't prove whether ribociclib works better than other options. Side effects may still occur with long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beverly Hills Cancer Center
Beverly Hills, California, 90211, United States
-
Duly Health and Care
Plainfield, Illinois, 60585, United States
-
Eastchester Center for Cancer Care
The Bronx, New York, 10469, United States
-
Englewood Health
Englewood, New Jersey, 07631, United States
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Indian Univ Health Goshen Center forCancer
Goshen, Indiana, 46526, United States
-
Ironwood Cancer and Research Centers
Chandler, Arizona, 85224, United States
-
John D Archbold Memorial Hospital
Thomasville, Georgia, 31792, United States
-
Mid Florida Hematology And Onc Ctr
Orange, Florida, 32763, United States
-
Millennium Research Clin Develop
Houston, Texas, 77090, United States
-
Northern Light Mercy Hospital
Portland, Maine, 04102, United States
-
Novartis Investigative Site
San Juan, J5402DIL, Argentina
-
Novartis Investigative Site
Natal, Rio Grande do Norte, 59075 740, Brazil
-
Novartis Investigative Site
Ijuí, Rio Grande do Sul, 98700-000, Brazil
-
Novartis Investigative Site
Florianópolis, Santa Catarina, 88020-210, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 01317 000, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 03102, Brazil
-
Novartis Investigative Site
Sao Jose Rio Preto, 15090 000, Brazil
-
Novartis Investigative Site
São Paulo, 01255-000, Brazil
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 404100, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050011, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150081, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310016, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Qingdao, 266000, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300480, China
-
Novartis Investigative Site
San José, 95008, Costa Rica
-
Novartis Investigative Site
Heraklion Crete., 715 00, Greece
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751007, India
-
Novartis Investigative Site
Delhi, 110085, India
-
Novartis Investigative Site
Meldola, FC, 47014, Italy
-
Novartis Investigative Site
Osaka, Osaka, 5400006, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138431, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
El Chouf, LBN, 1503-2010, Lebanon
-
Novartis Investigative Site
Beirut, 1100 2070, Lebanon
-
Novartis Investigative Site
Beirut, 113-0236, Lebanon
-
Novartis Investigative Site
San Pedro G G, 66278, Mexico
-
Novartis Investigative Site
Trujillo, La Libertad, 13011, Peru
-
Novartis Investigative Site
San Borja, Lima region, 41, Peru
-
Novartis Investigative Site
Gdansk, 80-214, Poland
-
Novartis Investigative Site
Lisbon, 1400-038, Portugal
-
Novartis Investigative Site
Loures, 2674-514, Portugal
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Cape Town, 7500, South Africa
-
Novartis Investigative Site
Johannesburg, 2196, South Africa
-
Novartis Investigative Site
Pretoria, 0002, South Africa
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Sant Joan Despí, Barcelona, 08970, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taipei, 11217, Taiwan
-
Novartis Investigative Site
Malatya, Battalgazi, 44280, Turkey (Türkiye)
-
Novartis Investigative Site
Diyarbakır, Sur, 21280, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kecioren Ankara, 06010, Turkey (Türkiye)
-
Novartis Investigative Site
Hanoi, 100000, Vietnam
-
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, 74136, United States
-
Poudre Valley Hospital
Fort Collins, Colorado, 80528, United States
-
Summit Cancer Care
Savannah, Georgia, 31405, United States
-
The Valley Hospital-Luckow Pavillion
Paramus, New Jersey, 07652, United States
-
University Hospitals of Cleveland Seidman Cancer Center
Cleveland, Ohio, 44106, United States